ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MDXG MiMedx Group Inc

7.37
-0.13 (-1.73%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
MiMedx Group Inc NASDAQ:MDXG NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.13 -1.73% 7.37 5.85 8.25 7.7505 7.36 7.65 832,074 05:00:02

MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9

02/03/2021 1:00pm

GlobeNewswire Inc.


MiMedx (NASDAQ:MDXG)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more MiMedx Charts.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2020 after the market close on Monday, March 8, 2021. MiMedx management will host a webcast and conference call to review its results on Tuesday, March 9, 2021, beginning at 9:30 am, Eastern Time. Participating on the call will be Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development.

This conference call can be accessed using the following information:

Webcast: https://edge.media-server.com/mmc/p/outonjvn U.S. Investors: 877-359-9508International Investors: 224-357-2393Conference ID: 4786292

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MiMedxMiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:InvestorsJack Howarth404-360-5681investorrelations@mimedx.com

 

1 Year MiMedx Chart

1 Year MiMedx Chart

1 Month MiMedx Chart

1 Month MiMedx Chart

Your Recent History

Delayed Upgrade Clock